Coronavirus | Affected host | Intermediate host | Potential reservoir host | Disease | Cell receptor | |
---|---|---|---|---|---|---|
SARS-CoV | Humans | Himalayan palm civet/raccoon | Bat | SARS | ACE2 | |
MERS-CoV | Humans | Dromedary camels | Bat | MERS | DPP4 (Dipeptidyl peptidase 4) | |
SARS-CoV-2 | Humans | NA (No report) | NA (No report) | COVID-19 | ACE2 |
Study | Chen N. |
Huang C. |
Alsofayan Y.M. |
Shabrawishi M. |
---|---|---|---|---|
Patient count | 99 | 41 | 1519 | 150 |
Age (mean, year) | 55.5 | 49 | 37 | 46.1 |
Fever | 83% | 98% | 86% | 49% |
Cough | 82% | 76% | 89% | 49% |
Shortness of breath | 31% | 55% | – | 20% |
Myalgia | 11% | 44% | 29% | 3% |
Hemoptysis | – | 5% | – | 0.4% |
Sputum production | – | 28% | – | 3% |
Confusion | 9% | – | – | – |
Sore throat | 5% | – | 82% | 16% |
Rhinorrhea | 4% | – | 72% | 6% |
Chest pain | 2% | – | – | – |
Diarrhea | – | 3% | 14% | 1% |
Headache | – | 8% | 27% | 3% |